-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $222

Benzinga·07/31/2026 13:59:20
Listen to the news
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $222.